$3.94
▲ +$0.01
(+0.25%)
Vol 5.5M
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.5B
ROE
-532.6%
Margin
-3912.9%
D/E
221.86
Beta
1.12
52W
$1–$5
Wall Street Consensus
9 analysts · Apr 20262
Strong Buy
5
Buy
2
Hold
0
Sell
0
Strong Sell
77.8%
Buy Rating
Price Chart
Similar Stocks
ARDX
Ardelyx Inc
$1.4B
VIR
Vir Biotechnology Inc
$838.9M
IOVA
Iovance Biotherapeutics Inc
$1.1B
GLUE
Monte Rosa Therapeutics Inc
P/E 48.7
$1.0B
BCAX
Bicara Therapeutics Inc
$922.0M
OLMA
Olema Pharmaceuticals Inc
$2.0B
ZBIO
Zenas Biopharma Inc
$2.3B
TSHA
Taysha Gene Therapies Inc
$1.5B
NVAX
Novavax Inc
P/E 3.2
$1.1B
Earnings
Beat rate: 40.0%
Next Report
May 12, 2026
EPS Estimate: $-0.03
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.03 | — | — |
| Dec 2025 | $-0.09 | $-0.07 | +$0.02 |
| Sep 2025 | $-0.10 | $-1.06 | $-0.96 |
| Jun 2025 | $-0.08 | $-0.09 | $-0.01 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -346.7% | -346.7% | -346.7% | -346.7% | -532.6% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -3112.4% | -2868.7% | -2868.7% | -2868.7% | -2868.7% | -3912.9% |
| Gross Margin | -27.6% | -0.7% | -0.7% | -0.7% | -0.7% | 30.3% |
| D/E Ratio | — | 0.00 | 0.00 | 0.00 | 0.00 | 221.86 |
| Current Ratio | 2.71 | 2.71 | 2.71 | 2.71 | 2.71 | 4.04 |
Key Ratios
ROA (TTM)
-180.5%
P/S (TTM)
234.42
P/B
4.9
EPS (TTM)
$-0.82
CF/Share
$-0.34
Rev Growth 3Y
-35.0%
52W High
$5.23
52W Low
$0.69
$0.69
52-Week Range
$5.23
How does PGEN compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
PGEN valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
234.4
▲
1724%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
4.9
▲
100%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
PGEN profitability vs Biotechnology peers
ROE
-532.6%
▼
691%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-3912.9%
▼
1265%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
30.3%
▼
61%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-180.5%
▼
286%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
PGEN financial health vs Biotechnology peers
D/E ratio
221.9
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
4.0
▼
9%
below
peers
(4.4)
vs Peers
vs Industry
In line
Beta
1.1
▲
16%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
PGEN fundamentals radar
PGEN
Peer median
Industry
PGEN profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
PGEN vs peers: key metrics
Latest News
No related news yet